B. Riley raised the firm’s price target on Theravance Biopharma (TBPH) to $17 from $14 and keeps a Neutral rating on the shares. The final generic settlement with Mankind (MNKD) locks exclusivity through April 2039, “removing the last overhang on a clean single-asset story,” the analyst tells investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TBPH:
- Theravance Secures Long-Term YUPELRI Patent Litigation Settlement
- Theravance Biopharma price target raised to $15 from $13 at TD Cowen
- Theravance Biopharma: Post‑CYPRESS Restructuring Leaves Limited Upside and Justifies Neutral Stance
- Theravance Biopharma reports Q4 EPS $1.15, consensus $1.10
- Theravance Biopharma options imply 3.2% move in share price post-earnings